Core Viewpoint - Northeast Pharmaceutical (000597) has completed the acquisition of a 70% stake in Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. for approximately 187 million yuan, enhancing its capabilities in TCR-T and CAR-T cell therapy technologies and product transformation systems [1] Group 1: Acquisition Details - The acquisition was finalized on November 2024, with a cash payment of about 187 million yuan [1] - The company has gained access to a technology platform and product transformation system in the TCR-T and CAR-T cell therapy fields [1] Group 2: Product Development - Dingcheng Peptide Source's core product, DCTY1102 injection, has received implied approval for clinical trials from the CDE, positioning it to become the second globally and the first domestically targeted KRAS G12D TCR-T cell drug to enter Phase I clinical trials [1] - Another product, DCTY0801, has successfully obtained orphan drug designation from the FDA in the United States [1]